论文部分内容阅读
人乙肝免疫球蛋白HepagamB商品名:HepagamB研制公司:加拿大Cangene公司新增适应证:用于防止乙肝表面抗原呈阳性的肝移植病人的肝炎复发。HepagamB于2006年1月首先在美国获准用于治疗乙肝病毒的急性接触。HepagamB是一种免疫球蛋白,可为接触乙肝病毒有感染风险的患者提供短期应
Human hepatitis B immunoglobulin HepagamB Trade Name: HepagamB Development Company: Canada’s Cangene Company New Indications: Hepatitis Recurrence for Liver Transplant Patients to Prevent Hepatitis B Surface Antigen Positive. HepagamB was first approved in the United States in January 2006 for the treatment of acute hepatitis B virus exposure. HepagamB is an immunoglobulin that provides short-term response to patients exposed to hepatitis B virus infection